Diginex completes $100m in acquisitions since 2025 listing

Diginex said it has completed over $100 million of acquisitions, including Matter DK ApS for $13 million, The Remedy Project for $7.6 million and Plan A for $80 million, while also signing a reseller deal that could generate up to $40 million in revenue over four years. Founder Miles Pelham has invested $25.4 million since the IPO at an average $5.65 per share, but the stock is still trading at $0.90, down 99% over the past year and near its 52-week low. The company also extended the outside date for its proposed $1.5 billion all-share Resulticks acquisition to May 31, 2026.

Analysis

The market is pricing DGNX less like a growing software roll-up and more like a financing vehicle with execution risk. That creates a classic asymmetry: if the company can actually integrate acquisitions and convert reseller access into booked revenue, the equity can re-rate violently from a tiny base; if not, the capital structure and dilution path dominate and the stock remains a value trap. The key second-order issue is that each acquisition raises the bar for integration while also increasing the number of stakeholders whose consideration can turn into future working-capital or earnout pressure.

The bigger tell is not the announced strategy, but the disconnect between enterprise ambition and market confidence. With a sub-$30M equity value, any meaningful purchase consideration or deferred payment becomes highly dilutive unless funded off-balance-sheet or via stock at depressed levels; that makes “growth by acquisition” self-reinforcing only if the underlying assets are immediately cash generative. The reseller angle is also more important than it looks: if channel economics work, it is the fastest path to validating product-market fit without more balance-sheet strain, but if conversion is weak, it becomes a story of headline ARR that never translates into cash.

Contrarian take: the move may be over-discounted on the downside because the stock has already priced in failure, but it is under-appreciated how fragile the upside path is. This is the kind of setup where small operational misses create outsized equity damage, while any credible evidence of post-merger integration or signed revenue from the reseller channel can trigger a sharp squeeze. Over the next 1-3 months, the most important catalyst is not more deal announcements; it is whether management can show disciplined revenue recognition, cash preservation, and reduced reliance on insider support.

Key Decisions for Investors

• Avoid outright long exposure in DGNX until there is evidence of cash conversion; the risk/reward is poor because the downside is likely driven by dilution or failed integration over the next 1-3 quarters.
• For event-driven traders, consider a small tactical long only on confirmation of booked revenue from the reseller relationship or post-close synergy disclosure; target a 2-3x move off the depressed base, but keep a tight stop on any follow-up equity issuance.
• Pair trade idea: long a profitable, self-funded ESG/data software peer versus short DGNX to express the quality-vs-roll-up spread; the trade benefits if the market re-rates execution quality and penalizes acquisition-led growth.
• If options are liquid, use call spreads rather than stock for upside speculation in DGNX; the optionality is attractive only if the next catalyst proves integration, while downside remains binary and dilution-sensitive.
• Set a hard review trigger around the next financing or acquisition disclosure; if consideration is stock-heavy or contingent, treat that as a signal to short rallies rather than chase them.